RVNC
Revance Therapeutics, Inc.
7.37
USD
This page is just a preview of the data found in TrendSpider’s full version
Revance Therapeutics, Inc. stock is up 6.66% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 9 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 10 CALLs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 28 Nov 18:30 | 19 Jan, 2024 | 10.00 | 922 | ||
| 29 Nov 15:45 | 17 Jan, 2025 | 7.50 | 73 | ||
| 29 Nov 15:45 | 17 Jan, 2025 | 7.50 | 73 | ||
| 29 Nov 15:45 | 17 Jan, 2025 | 7.50 | 73 | ||
| 29 Nov 15:45 | 17 Jan, 2025 | 7.50 | 73 | ||
| 29 Nov 15:45 | 17 Jan, 2025 | 7.50 | 73 | ||
| 29 Nov 15:46 | 17 Jan, 2025 | 7.50 | 73 | ||
| 04 Dec 16:26 | 17 Jan, 2025 | 7.50 | 1225 | ||
| 08 Dec 15:16 | 17 Jan, 2025 | 7.50 | 1480 | ||
| 08 Dec 17:43 | 17 Jan, 2025 | 7.50 | 1480 |
Revance Therapeutics, Inc. engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia.
